Mexico: Pharmaceutical Industry Infrastructure Overview

Introduction

Mexico is one of the most attractive pharmaceutical markets in the Latin American region. It is increasingly aligning its regulations and legislation with US standards, and in 2008 abolished the requirements for pharma companies to have a manufacturing plant in Mexico, therefore lowering barriers to market entry for multinationals.

Features and benefits

* Understand drivers and resistors for accessing the Mexican pharmaceutical market
* Analyze ongoing trends in the R&D and manufacturing sector in Mexico
* Examine the leading pharmaceutical companies in Mexico, their infrastructure and current strategy in this market
* Overview of outsourcing and distribution trends in the Mexican pharmaceutical market

Highlights

The Mexican pharmaceutical market generated $14.3bn in sales during 2010, with an annual growth rate of 8.3% between 2009 and 2010, and a compound annual growth rate of 2.0% between 2006 and 2010.
Several government incentives are encouraging pharma companies to enter the Mexican market, with the country increasingly aligning its regulations and legislation with US standards. The government is stimulating the development of private-public partnerships and favorable R&D tax incentives.
Despite improvements, a lack of regulatory transparency coupled with widespread corruption still exists. Also, Mexico’s reliance on the US can hamper potential growth of this market, and as a result, it is not surprising that Mexico was negatively impacted during the recession.

Your key questions answered

* What are the government subsidies to facilitate investments in the Mexican market?
* Which are the top 10 pharmaceutical companies, and how have these expanded their business operations?
[Studien Infos ausblenden]

Executive Summary
Mexico – Introduction
Mexico – Strategic scoping and focus
Mexico – Key findings
R&D trends
Manufacturing trends
Related reports
MEXICO – PHARMACEUTICAL INDUSTRY INFRASTRUCTURE ANALYSIS
Mexico – Pharmaceutical industry metrics
Pharmaceutical sales
Imports versus domestically manufactured drug usage
Import of pharmaceuticals in Mexico is facilitated by NAFTA
Mexico – R&D trends
R&D in Mexico is driven by four regional bioclusters
Regulations for conducting clinical trials in Mexico are improving
Mexico is set to become a major outsourcing destination
Mexico – Manufacturing trends
Mexico – Distribution trends
Mexico – Key company infrastructure
Eli Lilly
Sanofi
Pfizer
Bayer Schering
Merck & Co.
Roche
Novartis
Johnson & Johnson
GlaxoSmithKline
Boehringer Ingelheim
AstraZeneca
BIBLIOGRAPHY
Mexico – Publications and online articles
Mexico – Datamonitor reports
APPENDIX
Exchange rates used in this report
[Inhaltsverzeichnis ausblenden]